ALLIANCE PHARMA PLC

Report Publication Announcement • Aug 1, 2017

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 6570M

Alliance Pharma PLC

01 August 2017

For immediate release	1 August 2017

ALLIANCE PHARMA PLC

("Alliance" or the "Company")

Notification of Interim Results

Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, will announce its interim results for the six months ended 30 June 2017 on Wednesday 13 September 2017.

A briefing for analysts will be held at 11.00am on the morning of the results at the offices of Buchanan, 107 Cheapside, London EC2V 6DN.

For more information, or to register attendance, please contact Buchanan on 020 7466 5000.

For further information:

Alliance Pharma plc	+ 44 (0) 1249 466966
John Dawson, Chief Executive Officer Peter Butterfield, Deputy Chief Executive Officer Andrew Franklin, Chief Financial Officer
www.alliancepharma.co.uk
Buchanan	+ 44 (0) 20 7466 5000
Mark Court / Sophie Cowles
Numis Securities Limited	+ 44 (0) 20 7260 1000
Nominated Adviser: Michael Meade / Freddie Barnfield
Corporate Broking: James Black / Toby Adcock

Notes to editors:

About Alliance Pharma

Alliance, founded in 1998, is an international speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The Company has sales in more than 100 countries worldwide via direct sales, joint ventures and a network of distributors.  Alliance has a strong track record of acquiring the rights to established niche products and it currently owns or licenses the rights to approximately 90 pharmaceutical and consumer healthcare products. The Company continues to explore opportunities to expand its product portfolio.

Alliance joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NORRBMFTMBIJBLR